NasdaqHealth CareBiological Products, (No Diagnostic Substances)SAINT-LAURENT, Quebec, CanadaPrimary ticker: ENGN

enGene Therapeutics Inc. ENGNW

ENGNW is a enGene Therapeutics Inc. warrant listed on Nasdaq. Its price is shown below; holders, insider trades and filings are for the company. The company’s common stock is ENGN →

CIK 1980845

Insider trades, 12 mo

1 buy · 0 sells

$10.1K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders

—

Not linked to 13F reports yet

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in enGene Therapeutics Inc.'s latest quarterly report, compared with the one before.

Filed Sep 8, 2026 · Quarter ended Jul 31, 2026

Compared with the 10-Q for the quarter ended Apr 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in enGene Therapeutics Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

1 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Sep 22, 2026. Insiders have two business days to file.

Recent insider trades

William Grossman Interim Chief Medical Officer, Director	Sep 22 Form 4 ↗	Buy	+$10.1K 5,102 sh @ $1.97	+20.0%
Forbion Growth Management B.V. 10% owner	Oct 30, 2024 Form 4 ↗	Buy	+$5.0M 561,797 sh @ $8.90	-102.3%
Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Oct 8, 2024 Form 4 ↗	Buy	+$5,280 800 sh @ $6.60	-97.7%
Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Oct 7, 2024 Form 4 ↗	Buy	+$77.6K 11,844 sh @ $6.55	-96.8%
Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Oct 4, 2024 Form 4 ↗	Buy	+$39.2K 5,997 sh @ $6.54	-95.3%

All ENGNW insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

2.46M shares

Funds that report this stock, checked against market prices.

Reports for the quarter ending Sep 30, 2026 are still coming in (2 positions so far, against 11 the quarter before), so we compare the two complete quarters before it.

Q2 2026. Only one quarter of reports so far, so nothing to compare yet.

Top 13F holders
#
1	BVF Inc 13F ↗	945,402	$274.1K
2	Blue Owl Capital Holdings LP 13F ↗	511,177	$148.2K
3	Caption Management, LLC 13F ↗	333,675	$96.7K
4	LMR Partners LLP 13F ↗	309,763	$89.8K
5	Aristeia Capital, LLC 13F ↗	197,678	$47.7K
6	D. E. Shaw & Co., Inc. 13F ↗	104,622	$30.3K
7	Toronto Dominion Bank 13F ↗	31,545	$9,148
8	StoneX Group Inc. 13F ↗	10,371	$8,918
9	CSS LLC 13F ↗	16,895	$4,898
10	Clear Street Group Inc. 13F ↗	200	$58

Download CSV Every fund that holds ENGNW, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What enGene Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What enGene Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at enGene Therapeutics Inc.

0 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to enGene Therapeutics Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at enGene Therapeutics Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	1	1	1
2025 Q1	0	0	0
2025 Q2	0	0	0
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	0	0	0

All ENGNW applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2026	10	—	2.46M	$709.8K
Q3 2026	2	-8	512,521	$102.6K

Each point is a quarter-end, from Q2 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (29286X119). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes17 in 12 mo 8-K events2 in 90 days Patents6 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: enGene Therapeutics Inc.
Address: 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
Phone: (514) 332-4888
Fiscal year ends: Oct 31
Filer category: emerging growth company
Incorporated in: Canada (Federal Level)
Listed as: ENGN (Nasdaq), ENGNW (Nasdaq)
Former names: enGene Holdings Inc. (until 2026)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

Price of ENGNW, not of the company’s common stock

$0.22−$0.05 (−19.97%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.13 · High $0.2749Nov 13, 2026

Aug 13, 2026Low $0.13 · High $0.4301Nov 13, 2026

Nov 13, 2025Low $0.12 · High $4.20Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.